Search clinical trials for: PF-06882961 Immediate Release Solution

Total 680 results

Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium
Pfizer

Completed

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Healthy Subjects

United States
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Obesity

United States, Taiwan, Canada, Japan
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Pfizer

Completed

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

Obesity | Diabetes

United States
Pfizer

Completed

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Hungary, Taiwan, Bulgaria, Canada, Korea, Republic of, Poland, Slovakia
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Remedee SA

Completed

Evaluation of the Effectiveness of the Remedee Solution in Fibromyalgia (Fibrepik)

Fibromyalgia

France
Biogen

Completed

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

Healthy

United States
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
Pfizer

Completed

PF-06651600 Taste Study.

Healthy Participants

Belgium
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Santen Pharmaceutical Asia Pte. Ltd.

Recruiting

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NOPAPS)

Ocular Hypertension | Primary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma, Suspect

Korea, Republic of
Pfizer

Completed

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Plaque Psoriasis

United States
Merck Sharp & Dohme LLC

Completed

Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)

Dry Eye Disease
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
NYU Langone Health

Completed

Envarsus XR in Lung Transplant

Lung Transplant

United States
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Parion Sciences

Terminated

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Rigshospitalet, Denmark
Karolinska Institutet; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Recruiting

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

CLL

Denmark, Sweden, Netherlands
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Tulane University
National Institute of General Medical Sciences (NIGMS)

Completed

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial (NICE)

Chronic Kidney Disease

United States
Pfizer

Completed

First In Human Study Of Increasing Oral Doses Of PF-04634817

Healthy

United States
Pfizer

Completed

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Hepatitis C Virus

United States
King Edward Medical University

Unknown

Comparison of Outcome of Post Burn Flexion Contracture Release Under Tourniquet Verses Tumescent Technique in Children

Flexion Contracture | Hand Burns
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Leber's Hereditary Optic Neuropathy

United States

3

Subscribe